The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs
Abstract
The purpose of this work was to improve the oral bioavailability of poorly soluble drugs by incorporation into solid lipid nanoparticles (SLNs). All-trans retinoic acid (ATRA) was used as a poorly soluble model drug. Different formulations of SLNs loaded with ATRA were successfully prepared by a high-pressure homogenization method and using Compritol 888 ATO as lipid matrix. The particle size and distribution, drug loading capacity, drug entrapment efficiency (EE %), zeta potential, and long-term physical stability of the SLNs were investigated in detail. Drug release from two sorts of ATRA-SLN was studied and compared with the diffusion from ATRA solution in 0.1 M HCl, distilled water and phosphate buffer (pH 7.40), using a dialysis bag method. A pharmacokinetic study was conducted in male rats after oral administration of 8 mg kg−1 ATRA in different formulations and it was found that the relative bioavailability of ATRA in SLNs was significantly increased compared with that of an ATRA solution. The amount of surfactant also had a marked effect on the oral absorption of ATRA with SLN formulations. Although an emulsion formulation also increased ATRA absorption, it was too unstable for use in clinical situations. The absorption mechanism of the SLN formulations was discussed. These results indicate that ATRA absorption is enhanced significantly by employing SLN formulations. SLNs offer a new approach to improve the oral bioavailability of poorly soluble drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150
Improving drug solubility for oral delivery using solid dispersions
Leuner, C. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00076-x · Cited by 2,574
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism
zur Mühlen, A., Schwarz, C., & Mehnert, W. (1998) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(97)00150-1 · Cited by 945
Handbook of Pharmaceutical Controlled Release Technology
Wise, D. L. (2000) · CRC Press eBooks · doi:10.1201/9781482289985 · Cited by 768
Schwarz, C., Mehnert, W., Lucks, J. S., & Müller, R. H. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90047-7 · Cited by 574
The Gut as a Barrier to Drug Absorption: Combined Role of Cytochrome P450 3A and P-Glycoprotein
Zhang, Y., & Benet, L. Z. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140030-00002 · Cited by 518
Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., & Yang, C. Z. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00007-3 · Cited by 476
Lipid-based formulations for intestinal lymphatic delivery
O’Driscoll, C. M. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00051-9 · Cited by 372
Gao, P., Rush, B. D., Pfund, W. P., Huang, T., Bauer, J. M., Morozowich, W., Kuo, M., & Hageman, M. J. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10511 · Cited by 361
Microemulsion formulation for enhanced absorption of poorly soluble drugs
Kawakami, K., Yoshikawa, T., Moroto, Y., Kanaoka, E., Takahashi, K., Nishihara, Y., & Masuda, K. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00049-4 · Cited by 306
Zhang, H., Yao, M., Morrison, R. A., & Chong, S. (2003) · Archives of Pharmacal Research · doi:10.1007/bf02976689 · Cited by 242
SCHWARZ, C. (1999) · Journal of Microencapsulation · doi:10.1080/026520499289185 · Cited by 235
Microemulsion formulation for enhanced absorption of poorly soluble drugs
Kawakami, K., Yoshikawa, T., Hayashi, T., Nishihara, Y., & Masuda, K. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00050-0 · Cited by 188
Production of solid lipid nanoparticles (SLN): scaling up feasibilities
Dingler, A., & Gohla, S. (2002) · Journal of Microencapsulation · doi:10.1080/02652040010018056 · Cited by 143
Improving the Oral Bioavailability of Albendazole in Rabbits by the Solid Dispersion Technique
Kohri, N., Yamayoshi, Y., He, X., Iseki, K., Sato, N., Todo, S., & Miyazaki, K. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991772277 · Cited by 140
Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats.
Wauwe, J. P. V., Coene, M. C., Goossens, J., Cools, W., & Monbaliu, J. G. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13356-9 · Cited by 136
Woo, J. S., Lee, C. H., Shim, C. K., & Hwang, S. (2003) · Pharmaceutical Research · doi:10.1023/a:1022286422439 · Cited by 133
PHARMACOKINETICS OF DOXORUBICIN INCORPORATED IN SOLID LIPID NANOSPHERES (SLN)
Zara, G. P., Cavalli, R., Fundaro', A., Bargoni, A., Caputo, O., & Gasco, M. R. (1999) · Pharmacological Research · doi:10.1006/phrs.1999.0509 · Cited by 122
Miyake, K., Arima, H., Hirayama, F., Yamamoto, M., Horikawa, T., Sumiyoshi, H., Noda, S., & Uekama, K. (2000) · Pharmaceutical Development and Technology · doi:10.1081/pdt-100100556 · Cited by 120
Inclusion complexes of tretinoin with cyclodextrins
Montassier, P., Duchêne, D., & Poelman, M.-C. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00104-x · Cited by 93
Ketoconazole inhibits the in vitro and in vivo metabolism of all-trans-retinoic acid.
Wauwe, J. P. V., Coene, M. C., Goossens, J., Nijen, G. V., Cools, W., & Lauwers, W. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22669-6 · Cited by 86
Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion
Nicolaos, G., Crauste–Manciet, S., Farinotti, R., & Brossard, D. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00365-x · Cited by 86
Scaling up feasibility of the production of solid lipid nanoparticles (SLN).
Gohla, S., & Dingler, A. (2001) · PubMed · Cited by 78
Seeballuck, F., Ashford, M. B., & O’Driscoll, C. M. (2003) · Pharmaceutical Research · doi:10.1023/a:1024422625596 · Cited by 73
Giannini, F., Maestro, R., Vukosavijevic, T., Pomponi, F., & Boiocchi, M. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970117)70:2<194::aid-ijc10>3.0.co;2-j · Cited by 73
Estey, E., Thall, P., Mehta, K., Rosenblum, M., Brewer, T. J., Simmons, V, Cabanillas, F., Kurzrock, R., & Lopez-Berestein, G. (1996) · Blood · doi:10.1182/blood.v87.9.3650.bloodjournal8793650 · Cited by 66
Defer, G., Adle‐Biassette, H., Ricolfi, F., Martin, L., Authier, F., Chomienne, C., Degos, L., & Degos, J. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005701507111 · Cited by 64
Dirks, P. B., Patel, K., Hubbard, S. L., Ackerley, C. A., Hamel, P. A., & Rutka, J. T. (1997) · Oncogene · doi:10.1038/sj.onc.1201392 · Cited by 62
Clinical pharmacology of all-trans retinoic acid.
Muindi, J. R., Young, C. W., & Warrell, R. P. (1994) · PubMed · Cited by 61
Retinoic acid induced death of ovarian carcinoma cells correlates with c‐myc stimulation
Krupitza, G., Hulla, W., Harant, H., Dittrich, E., Kállay, E., Huber, H. P., Grunt, T. W., & Dittrich, C. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610511 · Cited by 59
Clinical Pharmacokinetics of Tretinoin
Regazzi, M. B., Iacona, I., Gervasutti, C., Lazzarino, M., & Toma, S. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00004 · Cited by 56
Wayne State University (1995) · Lung Cancer · doi:10.1016/0169-5002(95)96296-8 · Cited by 55
Holm, R., Müllertz, A., Christensen, E., Høy, C., & Kristensen, H. G. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00186-5 · Cited by 44
Irving, H., Lovat, P. E., Hewson, Q. C., Malcolm, A. J., Pearson, A. D. J., & Redfern, C. P. F. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10027-2 · Cited by 29
Cited by
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Khadka, P., Ro, J., Kim, H., Kim, I., Kim, J. T., Kim, H., Cho, J. M., Yun, G., & Lee, J. (2014) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.05.005 · Cited by 998
The present and future of nanotechnology in human health care
Sahoo, S. K., Parveen, S., & Panda, J. J. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2006.11.008 · Cited by 905
Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery
Das, S., & Chaudhury, A. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-010-9563-0 · Cited by 838
Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics
Bhalani, D. V., Nutan, B., Kumar, A., & Singh Chandel, A. K. (2022) · Biomedicines · doi:10.3390/biomedicines10092055 · Cited by 704
Metadata
- Authors
- Hu, L., Tang, X., & Cui, F.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-12-01
- Volume
- 56
- Issue
- 12
- Pages
- 1527-1535
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W2135738686
- Cited by
- 281
- References
- 35
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.